van Rossum EF, Voorhoeve PG, te Velde SJ, Koper JW, Delemarre-van de Waal HA, Kemper HC et al
Compounded semaglutide is prepared by FDA-registered, inspected compounding pharmacies to meet specific patient needs, often when there are shortages of branded products
Researchers found 8.9% of these patients on semaglutide had NAION compared with 1.8% on other drugs, over a three-year period
503B outsourcing facilities offer more oversight than 503A pharmacies
So any lipotropic regimen should only proceed under specialist supervision
The good news is that the SURMOUNT-5 trial found no statistically significant difference in GI side effect rates between the two medications at their respective therapeutic doses